• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 4, 2016

View Archived Issues

Financings

Orchard Therapeutics Ltd., of London, launched with a £21 million (US$30.5 million) series A round led by F-Prime Capital. The company also inked partnerships with University College London, Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester, the University of California, Los Angeles, and Boston Children's Hospital for the development of gene therapies for serious and life-threatening orphan diseases. Orchard's development programs focus on the potential of ex vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases and hematological disorders. The lead candidate, a lentiviral stem cell gene therapy, is in development for severe combined immunodeficiency caused by adenosine deaminase deficiency. Read More

In the clinic

Evoke Pharma Inc., of Solana Beach, Calif., said it expects to provide top-line results from its pivotal phase III trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter. The company confirmed that 205 subjects have been randomized in the trial testing the nasal delivery formulation of metoclopramide. Read More

Other news to note

Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it submitted briefing material and a meeting request to the FDA to discuss the filing of a new drug application for Raxone (idebenone) for the treatment of Duchenne muscular dystrophy (DMD) patients not taking concomitant glucocorticoids. Read More

Earnings

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., reported $10 million in net revenues from first quarter U.S. sales of its pancreatic cancer drug, Onivyde (irinotecan liposome injection), which was launched in October 2015. Read More

Regulatory front

Impax Laboratories Inc., of Hayward, Calif., is suing New York-based Turing Pharmaceuticals AG for breach of contract involving sales of Daraprim (pyrimethamine). Read More

Tackling counterfeit drugs, India bolsters track-and-trace efforts

HYDERABAD, India – India is strengthening its "track and trace" system for drugs by making it mandatory to put online information about barcodes on the packing of drugs being exported. Read More

Counterfeits, trade secret theft plague drug, device industry

In an economy driven by global competition, counterfeits and theft of trade secrets remain major hazards for U.S. drug and device companies, handing them an uneven playing field in some parts of the world. Read More

Study identifies new therapeutic target for AMD

HONG KONG – A recent study by scientists at the Department of Ophthalmology and Visual Sciences of the Faculty of Medicine at the Chinese University of Hong Kong (CUHK) has identified a potential new therapeutic target for age-related macular degeneration (AMD), which is the leading cause of central vision loss in the elderly. Read More

Kynamro dealt to newco Kastle Therapeutics for potential $95M

Eight years after Ionis Pharmaceuticals Inc. selected then-independent Genzyme Corp. as the partner for its phase III lipid-lowering drug, mipomersen, in a potential $1.9 billion deal, the Carlsbad, Calif.-based company dealt the commercial asset, Kynamro, to start-up Kastle Therapeutics LLC for peanuts. Read More

Capital Ideaya: $46M take propels synthetic lethality; gene pairs kicked upstairs

Ideaya Biosciences Inc. CEO Yujiro Hata told BioWorld Today that "you'd be hard pressed to find a more personalized-medicine approach to cancer" than synthetic lethality, and his firm hopes to build on proof of concept brought about by the approval of Astrazeneca plc's poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) in BRCA-mutated advanced ovarian cancer. Read More

Spinning out hemophilia franchise, Biogen narrows focus to neurology

Biogen Inc. unveiled plans Tuesday to sharpen its focus on neurology by breaking its hemophilia business out into a new publicly traded company. The tax-free transaction is expected to be a boon for Biogen shareholders, but analysts were split on its broader implications. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe